According to the inventor of mRNA technology, the “vaccine” causes lipid nanoparticles to accumulate in “high concentrations” in the ovaries
The inventor of mRNA vaccine technology, Dr. Robert Malone said the lipid nanoparticles from the Covid vaccine leave the injection site and build up in organs and tissues. From Children’s Health Defense
In a three-hour conversation on the Dark Horse Podcast on June 10, 2021, Dr. Robert Malone, inventor of mRNA vaccine technology, with evolutionary biologist Brett Brownstein, Ph.D., on several safety concerns related to Pfizer and Moderna vaccines.
In the following short excerpt from the podcast, Malone, Brownstein and tech entrepreneur Steve Kirsch talk about the implications of Pfizer’s controversial Japanese biodistribution study. The study was launched earlier this month by Dr. Byram Bridle, a virus immunologist, made public.
They also address the lack of adequate animal testing for the new mRNA vaccines and the theory advocated by virologist Geert Vanden Bossche, Ph.D., that mass vaccination with the mRNA vaccines could produce more and more transmissible and potentially fatal variants.
The Defender reported on June 3 that Bridle received a copy of a Japanese biodistribution study – which had been withheld from the public – as a result of a request by the Freedom of Information Act (FOIA) to the Japanese government about Pfizer’s data.
Before the study was published, regulators and vaccine developers led the public to believe that the spike protein produced by the mRNA Covid vaccines stays in the shoulder where it was injected and is not biologically active. Though regulators around the world had a copy of the study that proved otherwise.
The biodistribution study that Bridle received showed that the lipid nanoparticles of the vaccine did not stay in the deltoid where they were injected, as the vaccine developers claimed, but circulated throughout the body and accumulated in organs and tissues in high concentrations including in the spleen, bone marrow, liver, adrenal glands and – in “fairly high concentrations” – in the ovaries.
The mRNA – or messenger RNA – gives the body the task of producing the spike protein. The lipid nanoparticles are like the “boxes” in which the mRNA is sent, according to Malone. “If you find lipid nanoparticles in an organ or tissue, it tells you that the drug has got to that place,” said the scientist.
According to the data from the Japanese study, lipid nanoparticles have been found throughout the blood, which circulates through the body within four hours. These then settle in large concentrations in the ovaries, the bone marrow and the lymph nodes.
Malone said recipients of the vaccine needed to be monitored for leukemia and lymphoma as there were concentrations of lipid nanoparticles in the bone marrow and lymph nodes. But these signals would often only show up after six months to nine years. Normally, such signals would be detected in animal experiments and long-term clinical studies, but this did not happen with the mRNA vaccines, he said.
There are two signals of adverse events, Malone said, that are now becoming apparent to the US Food and Drug Administration (FDA). One of them is thrombocytopenia – not enough platelets to be made in the bone marrow. The other is the reactivation of latent viruses. Malone found the signal from the ovaries particularly confusing because there was no accumulation in the testicles.
The original data packets would contain this biodistribution information, Malone said. And this data has been “out there for a long time in the protected, non-public area” of the global regulatory authorities.
According to Malone, the FDA knew that the Covid-Spike protein is biologically active and can spread from the injection site and cause adverse events, and that if it is biologically active, it is very dangerous. In fact, Malone was one of many scientists who warned the FDA of the dangers of free spike protein.
Malone also suggested that autoimmune problems could be related to the freely circulating spike protein. The developers assured, however, that this would not happen. Detecting autoimmune problems would require a two to three year follow-up period in Phase 3 patients to monitor possible autoimmune effects of vaccines – but this monitoring did not take place with the Pfizer and Moderna vaccines.
Pfizer and Moderna also failed to conduct adequate animal testing, Brownstein said. Animal testing would give us a signal that would alert us to what needs to be followed up in humans. The animal testing would suggest very alarming short-term effects, Brownstein said.
This is because the lipids and spike proteins would be in places where they shouldn’t be. They also have alarming signals regarding the dangers, damage and deaths that are reported in the system, and there are reasons to believe that there is a high number of unreported cases.
–
